In two multicenter, placebo controlled, phase 2 studies, patients with mild-to-moderate (n ¼ 161, Study 1) or severe (n ¼ 142, Study 2) erectile dysfunction (ED) were randomized to receive placebo, 0.05, 0.1, or 0.2 mg (Study 1) or placebo, 0.1, 0.2, or 0.3 mg (Study 2) of topically applied alprostadil (containing a proprietary skin permeation enhancer). The primary efficacy end point in both studies was the change in erectile function (EF) score from baseline to final visit. The changes from baseline for EF scores were À0.8 7 1.1, 1.8 7 1.1, 0.7 7 1.2, and 3.7 7 1.2 (Po0.01; Study 1) and 2.7 7 1.3, 6.29 7 1.4, 6.49 7 1.5, and 9.44 7 1.5 (Po0.001; Study 2) for ascending dose groups in each study. Topical alprostadil was well tolerated with the most common adverse event being urogenital pain. These results suggest this topical alprostadil formulation may be a potentially useful agent for the treatment of ED.
Introduction
Erectile dysfunction (ED) is a highly prevalent medical disorder that is estimated to affect over 152 million men worldwide. 1 ED is associated with such significant medical conditions as coronary artery disease, hypertension, hyperlipidemia, depression, and with medications, particularly antihypertensive and antidepressant drugs. 2 Despite the advent of an effective oral medication, sildenafil citrate, 3 for the treatment of erectile dysfunction, locally administered therapies remain as viable alternative treatments. Local therapies include intracavenosal injection therapy 4, 5 and intraurethral therapy. 6 The former is clearly more effective, 7 but more invasive and as such has resulted in relatively high drop-out rates of 40-50%. 8 Regardless of the method of delivery, the most commonly employed drug for local ED therapy is alprostadil, the synthetic formulation of prostaglandin E 1 . Alprostadil produces corporal smooth muscle relaxation predominately by the activation of adenylate cyclase and the subsequent accumulation of 3 00 5 00 -cAMP. 9 This mechanism is independent of the nitric oxideFcGMP mechanism and does not require sexual stimulation. As a result, alprostadil has demonstrated efficacy in patients in whom sildenafil has failed. 10 Topical application of alprostadil has to date been explored in phase 1 and in-office studies with modest results. [11] [12] [13] We herein present the first at-home phase 2 examination of the efficacy and safety of a topical application of alprostadil cream in doses of 0, 0.05, 0.1, 0.2, and 0.3 mg in combination with a novel, proprietary permeation enhancing agent (Alprox-TD s , NexMed Inc., Robbinsville, NJ, USA) for the treatment of mild-to-moderate and severe ED. Intensity of ED was determined by the erectile function domain score of the International Index of Erectile Function, 14 a validated instrument that also served as the instrument for measurement of efficacy.
Subject and methods
Two randomized, multicenter, parallel group, double-blind, placebo-controlled studies were conducted in accordance with Good Clinical Practice and International Conference on Harmonization guidelines, and in accordance with the ethical principles of the Declaration of Helsinki. Institutional Review Board approval was obtained by every clinic involved in either study, and all patients and their partners provided informed written consent before participation. In all, 12 and eight research clinics throughout the US participated in Studies 1 and 2, respectively.
Study 1. treatment of mild-to-moderate ED
Patients eligible for this study were between 21 and 65 years of age, had a diagnosis of ED of at least 3 months duration, had a monogamous and stable relationship with a consenting female partner, and were classified as having mild-to-moderate ED based on the IIEF Erectile Function Domain score of 14-21 (questions 1-5 and 15). Patients were excluded from participation in this study because of ED caused by untreated endocrine disease, clinically significant penile pathology (implant, excessive curvature, fibrosis, sexually transmitted disease), clinically significant renal or hepatic disease as determined via laboratory assay, and the use of prescribed or over the counter ED medication, supplements, or devices. Patients were required to discontinue the use of ED treatments prior to entry into the study.
After a screening visit (Visit 1) to assess baseline erectile function and safety measures (physical exams, laboratory tests, vital signs, and electrocardiogram), patients were randomly assigned in a blinded fashion to one of four treatment groups: placebo, 0.05, 0.1, or 0.2 mg alprostadil cream. Study medication contained alprostadil combined with a proprietary skin permeation-enhancing agent in a 100 mg cream formulation (Alprox-TD s , NexMed Inc., Robbinsville, NJ, USA). Medication was applied via a single-dose dispenser to the tip of the penis. The flaccid penis was held upright for 30 s as the medication was absorbed. Any excess medication was rubbed into the glans before sexual activity. The first dose of study medication was administered at the research clinic to assess local and systemic tolerance (Visit 2). Signs of intolerance were defined as a decrease in systolic blood pressure !30 mm Hg, a decrease in diastolic blood pressure !20 mmHg, or an increase in pulse rate !30 bpm. Orthostatic vital signs were measured at regular intervals up to 2 h postdosing. Patients who demonstrated blood pressure or heart rate changes as described above, regardless of the presence or absence of clinical symptoms, were dismissed from the study. Patients who tolerated the test dose were given five doubleblind doses of study medication to be used at home in conjunction with sexual intercourse over the next 3 weeks. Patients who used at least three doses of study medication during the interval between Visits 2 and 3 were allowed to continue the study and were given an additional five doses of study medication for at-home use. Diaries for recording efficacy and safety parameters were distributed to patients with study medication and were collected at each subsequent visit. At Visit 4, unused medication and diaries were returned to the clinic, and final efficacy and safety assessments were conducted.
The primary efficacy parameter was the change from baseline (Visit 2) to final visit (Visit 4) in the EF domain score of the IIEF.
14 Secondary efficacy parameters included the following: (a) change from baseline to final visit in the other domains of the IIEF as well as the overall IIEF score, (b) successful vaginal penetrations (relative to the number of attempts) based on diary responses (the Sexual Encounter Profile [SEP]), 15 (c) Patient SelfAssessment of Erection rating scale (PSAE), and (d) global assessment questionnaire (GAQ). The IIEF 14 and SEP 15 have been validated in previous clinical trials and have been shown to be useful instruments for assessing response to therapy. The SEP and PSAE were contained in patient diaries and were completed after every sexual encounter. The GAQ is a binary (yes/no) end point to the question 'has the treatment you have received improved your erections'. The GAQ was administered once at the conclusion of the study (Visit 4).
Safety was assessed during all clinic visits by monitoring adverse events and the use of concomitant medications, and evaluating changes in clinical laboratory tests, electrocardiograms, physical examination, and vital signs.
Study 2. Treatment of severe ED
Study 2 was identical in design to Study 1 with the following exceptions: (a) entry age was 21-70 y, (b) entry was limited to patients scoring o14 for the EF domain of the IIEF, and (c) doses used in Study 2 were 0, 0.1, 0.2, and 0.3 mg alprostadil contained in the same topical cream formulation.
Efficacy analyses: Changes from baseline in the EF domain score, changes from baseline in the other IIEF domain scores, and results of the PSAE were analyzed using an analysis of covariance (ANCOVA) model with treatment and study site as main factors, and baseline EF domain score as the covariate. Responses to the SEP questions were analyzed using a one-way analysis of variance (ANOVA) with treatment as a factor. The vaginal penetration success rate was analyzed as a weighted success rate using an ANOVA with treatment and number of attempts as factors. The Cochran-Mantel-Haenszel (CMH) test adjusting for site using ridit transformed scores was used to analyze the distribution of all Treatment of ED with topical alprostadil cream H Padma-Nathan et al possible responses to the GAQ and the distribution of responses under two categories: no improvement and some improvement. Demographic and baseline characteristics, study medication usage, and changes in vital signs after administration of the test dose were analyzed using either ANOVA models (continuous variables) or the CMH test (categorical variables).
Results

Patient demographics and disposition
In total, 161 and 142 patients were entered into Studies 1 and 2, respectively ( Table 1 ). The efficacy cohort for the primary efficacy end-point analysis comprised patients who met the following criteria: (a) used at least three doses of study medication at home in conjunction with attempts at sexual intercourse between Visits 2 and 3, (b) had both baseline and end of treatment efficacy data (IIEF), (c) had a baseline score on the IIEF erectile function domain score of 14-21 (Study 1) or o14 (Study 2), and (d) tolerated the test-dose at Visit 2, according to the stringent protocol definition of orthostatic hypotension. No significant differences among treatment groups for all demographic parameters were observed in either study population (Table 1) .
When compared with mild-to-moderate ED patients, severe ED patients tended to be older and a greater percentage of these patients reported secondary diagnoses of cardiovascular disease and diabetes. Nearly all patients had a history of ED of greater than 1 y.
Efficacy
In both studies, the primary efficacy end point (change in EF domain score relative to baseline) was significantly increased in the highest dose treatment group, and dose-related trends in efficacy for all treatment groups were observed. In Study 1, the change in EF domain score relative to baseline for the 0.2 mg treatment group was 3.771.2 compared with À0.871.1 for the placebo treatment group Figure 1) . Similarly, the change in total EF domain scores for the highest treatment groups in both studies was significant (Table 2) . In Study 1, the change in total EF domain score relative to baseline for the 0.2 mg treatment group was 7.272.5 compared with À1.772.2 for the placebo treatment group (Po0.01; Table 2 ). In Study 2, the change in total EF domain score relative to baseline for the 0.3 mg treatment group was 17.772.9 compared with 6.272.7 for the placebo treatment group (Po0.01; Table 2 ). Change in scores relative to baseline for questions 3 (ability to initiate and penetrate) and 4 (ability to maintain) were considered secondary end points (Table 2, Figure 2) . In Study 1, change in scores for both questions 3 and 4 was significantly improved (Po0.01) in the 0.2 mg treatment group. Similarly, in Study 2, scores for both questions 3 (Po0.05) and 4 (Po0.01) were significantly improved in the 0.3 mg treatment group. Significant changes in scores relative to baseline for the remaining domains of the IIEF were associated with treatment in Study 1 (data not presented). In Study 2, dose-related trends were observed, but were not significant (data not presented).
The patient diary contained the SEP and PSAE. Diaries were completed after every sexual encounter, and were returned to the clinics at the next visit (Table 3) . In Study 1, SEP questions 2-6 and total SEP score were associated with statistical significance (Po0.05) when compared with placebo. In Study 2, dose-related trends were observed for questions 2-6 and total score, but statistical significance was not achieved. The ratio of SEP question 3 to question 1 is reported in the literature as the vaginal penetration success rate (Table 4) . In Study 1, a significant difference among treatment groups (P ¼ 0.035) was observed and the 0.2 mg treatment group value was significantly different from placebo (Po0.01). In Study 2, a clear doserelated trend among treatment groups was present, but statistical significance was not achieved. The PSAE is a patient self-rating of erection, utilizing a scale from 1 to 5 (no rigidity to excessive rigidity; Table 5 ). In Study 1, the among-group comparison for all treatments was highly significant (Po0.001). In Study 2, the among-group comparison was also significant (Po0.009) for PSAE score.
At the conclusion of each study, a GAQ was administered to each patient as part of the exit visit. The GAQ is a sliding scale (1-7) ranging from no improvement to intense improvement in response to the question 'While using the study medication, did you feel your erections improved?' The percentage of patients reporting at least some improvement was highly significant (Po0.001) in both Study 1 (93% improvement at the 0.2 mg dose) and in Study 2 (83% improvement at the 0.3 mg dose). Interestingly, the placebo treatment groups reported improvements of 54 and 26% for Studies 1 and 2, respectively. Un- (Table 6 ).
15,17
Safety
Safety was assessed by monitoring adverse events and the use of concomitant medications, as well as evaluating changes in clinical laboratory tests, electrocardiograms (ECGs), physical examination, and vital signs.
Investigators in both studies were asked (in accordance with GCP and ICH guidelines) to assign a causal relation to each adverse event (definitely, probably, possibly, probably not, or definitely not related to the use of study medication). The reporting of adverse events considered to be definitely, probably, or possibly related to study medication is displayed in Table 7 . In general, the reporting of adverse events suggests a dose-relations in both studies. In both studies, the vast majority (497%) of adverse events were mild or moderate in intensity, were of short duration (60 min or less), and were considered by the investigator to be related to study medication. One serious adverse event was reported: a nearsyncopal episode, which followed a test dose of 0.2 mg and lasted 10 min. Rates of discontinuation because of adverse events suggested a dose-relation: 0, 6 (14%), 7 (18%), and 9 (23%) in the placebo, 0.05, 0.1 and 0.2 mg groups of Study 1, and 0, 1 (3%), 7 (20%), and 7 (20%) in the placebo, 0.1, 0.2, and 0.3 treatment groups in Study 2, respectively (Table 7) . Approximately, 2% of all adverse events reported were partner-related. The majority of adverse events reported by the partner were mild vaginal burning of short duration (less than 60 min, postintercourse).
Some adverse events resulted in the discontinuation of therapy for some patients in both studies ( Table 8 ). The majority of these discontinuation adverse events were related to urogenital pain. Adverse events of hypotension originated from two sources. Symptomatic hypotension adverse events (dizziness, faintness, and lightheadedness) were reported by patients during the administration of the test dose or during the at-home use of study medication. Asymptomatic hypotension adverse events were assigned by the investigator during the in-office test dose, when stringently defined vital sign changes (as described above in Patients and Methods) were met. Approximately, one-half of the hypotension adverse events listed in Table 8 There were no noteworthy effects of any dose of study medication on clinical laboratory tests, ECGs, or physical examinations.
Discussion
The management of ED today is enhanced by the availability of a broad range of treatment options. However, most men and couples consider oral drugs to be first-line therapy. As a result of the invasive nature of delivery of both intracavernosal injection therapy and intraurethral applications, the current positioning of locally delivered therapies is as 'second-line therapy'. Topical therapy may potentially overcome this hurdle, but only if efficacy is relatively high, that is, greater than that associated with intraurethral therapy. Although alprostadil is the gold-standard drug for local delivery, it is reasonable to expect that intraurethral applications and topical application of alprostadil share some similar venous channels (between the corpus spongiosum and the corpora cavernosa) for drug transfer. 16 However, topical application may have the advantage of transfer of drug through the deep and superficial dorsal vein. In addition, the presence of a permeation enhancer further facilitates the transfer of drug to the corporal smooth muscle. This is the first examination of the efficacy and safety of topical alprostadil in combination with a permeation enhancer (Alprox-TD s , NexMed Inc., Robbinsville, NJ, USA) in the treatment of ED in an at-home setting. These phase 2 studies are unique in that they encompass a broad range of intensities of ED as determined by the International Index of Erectile Function (IIEF). 14 In addition, the studies employed three well-established measures of 15 and (3) the GAQ. 3 The demographic results suggest the populations examined in these studies are typical of previously reported mild-to-moderate and severe ED populations in terms of age, duration of ED, and mean EF domain entry score. 3, 15 However, relative to many recently reported investigations of ED therapy 13, 15, 17 both studies contained greater percentages of patients with cardiovascular disease and diabetes. These disorders are associated with a lower level of response to pharmacological therapy for ED. In both studies, the primary efficacy end point (change in EF domain score relative to baseline) was significantly increased in the highest dose treatment group, and dose-related trends in efficacy for all treatment groups were observed. In the mild-tomoderate ED group (Study 1), the change in EF domain score relative to baseline for the 0.2 mg treatment group was 3.771.2 compared with À0.871.1 for the placebo treatment group (Po0.01; Table 1, Figure 1 ). In the severe ED group (Study 2), the change in EF domain score relative to baseline for the 0.3 mg treatment group was 9.471.5 compared with 2.771.3 for the placebo treatment group (Po0.01; Table 1, Figure 1 ). These changes in the EF domain are clinically meaningful and, in the severe study, even approximate that seen with oral sildenafil therapy. 3 The SEP diary data also supports the clinical significance of these EF domain changes. The percentage of successful penetration attempts (SEP question 3 to question 1) in the mild-to-moderate ED group (Study 1), a significant difference among treatment groups (P ¼ 0.035) was observed, while the 0.2 mg treatment group value was significantly different from placebo (Po0.01; Table 4 ). In the more severe ED group (Study 2), a clear dose-related trend among treatment groups was present, but statistical significance was not achieved. The percentage of patients reporting an improvement in erections was significantly greater in the active drug group in both studies (Po0.001): 93% for the 0.2 mg treatment group in the first study, and 83% for the 0.3 mg treatment group in the second study. These results again approximate those reported for sildenafil and other oral PDE5 inhibitor therapies. 3, 15, 17 Topical alprostadil in this study was well tolerated with the most common local adverse event being urogenital pain. This adverse event was *Considered by the investigator to be unrelated to the use of study medication. **This category contains both patient-reported AEs and protocol-dictated AEs as described in the text.
Treatment of ED with topical alprostadil cream H Padma-Nathan et al dose-related and was primarily localized to the application site. The vast majority of these adverse events (497%) were of mild or moderate intensity, and of short duration. Although changes in blood pressure were examined rigorously, hypotension was uncommon and half of the reported cases were asymptomatic and occurred during the in-office test dosing. The incidence of hypotension was therefore similar to that seen with intraurethral alprostail. 6 No cases of prolonged erections were reported. A single serious adverse event was reported in the entire phase 2 program.
Conclusion
In conclusion, these two phase 2 studies demonstrate that, in a population demonstrating a broad range of ED intensity, topical alprostadil (Alprox-TD s ) was both effective and well tolerated. These studies support the rationale for phase 3 studies, which are currently ongoing.
